• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Topical Imiquimod for High-Grade Cervical Lesions?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Surgical excision is the gold standard treatment for high-grade squamous intraepithelial lesions (HSIL) of the cervix
  • Imiquimod, an imidazoquinoline amine, inhibits viral replication and stimulates natural killer cells
    • FDA approved for treatment of external genital and perianal warts, small superficial basal cell carcinomas, and clinically typical actinic keratoses | Also used off-label for VIN and VAIN
  • Fonseca et al. (Obstetrics & Gynecology, 2021) evaluated the histologic response rate of HSIL after topical application of 5% imiquimod cream

METHODS:

  • Phase II randomized controlled trial
  • Participants
    • Cervical HSIL (CIN 2 or CIN3)
  • Interventions
    • 250 mg of 5% imiquimod cream applied to the cervix weekly for 12 weeks followed by LEEP
    • LEEP without preceding treatment
  • Study design
    • Outcomes stratified by human papillomavirus type and lesion grade
    • Analyses for both per protocol (PP) and Intention-to-treat (ITT)
  • Primary outcome
    • Rate of histologic regression (≤CIN 1) in LEEP specimens
  • Secondary outcomes
    • Surgical margin status
    • Adverse events

RESULTS:

  • Imiquimod: 49 women | LEEP only: 41 women
  • In the PP population, histologic regression was observed in more women vs imiquimod
    • Imiquimod + LEEP: 61%
    • LEEP only: 23%
    • P=0.001
  • More women in the imiquimod group had surgical margins that were negative for HSIL
    • Imiquimod + LEEP: 95%
    • LEEP only: 70%
    • P=0.004
  • Rates of adverse events for the imiquimod treatment group were similar in both the PP and ITT populations
    • PP: 74%
    • ITT: 78%
  • Adverse events were generally mild
    • Abdominal pain was the most common
  • Three patients in the imiquimod group had grade 2 adverse events, including
    • Vaginal ulcer
    • Vaginal pruritus with local edema
    • Moderate pelvic pain

CONCLUSION:

  • The weekly use of topical imiquimod promoted histologic regression of cervical HSIL
  • The authors state

Weekly topical treatment with imiquimod for 12 weeks is effective in promoting regression of cervical HSIL

One clinical application of these findings is the potential to use in larger lesions to achieve a higher rate of free surgical margins

We observed histologic regression (to CIN 1 or less) in more than half of patients, which suggests this might be an alternative treatment strategy to a cervical excision procedure

Learn More – Primary Sources:

Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What Are the Risk Factors for Recurrence after Large Loop Excision for CIN 2/3?
Natural History of CIN2 Lesions: Informing Practice Decisions
Treatment for Women with HIV and High-Grade Cervical Lesions: Cryotherapy or LEEP?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site